Bayer Caught in Legal Crosshairs from Brazil to Missouri as Operational Strength Takes a Back Seat

Bayer posts solid Q1 results with crop science growth, but markets focus on fresh Brazil glyphosate lawsuit and Missouri Roundup settlement challenges.

Bayer’s first-quarter results painted a picture of operational momentum, but the market’s focus has shifted squarely to the legal battlegrounds now stretching from South America to the American heartland. The stock struggled to keep pace with the broader DAX on Monday as fresh regulatory action in Brazil was followed by fresh courtroom challenges to the company’s multibillion-dollar Roundup settlement.

Brazil’s federal prosecutor has filed a lawsuit against the country’s health regulator Anvisa and the government itself, seeking to ban a Bayer glyphosate-based herbicide. The move underscores the global reach of the legal and regulatory headwinds the German conglomerate faces, even as its agricultural division posted robust quarterly numbers. Brazil is a critical market for Bayer’s crop science business, and the suit threatens to reignite uncertainty around a product line that already saw sales slide 15.1% in the first quarter.

On the other side of the world, Bayer’s carefully crafted $7.25 billion deal to resolve Roundup claims in Missouri is under attack. Attorneys representing 13 cancer patients last week filed a formal objection in the Circuit Court of the City of St. Louis, calling the proposed settlement unconstitutional and a “sweetheart deal” that allocates roughly $675 million in legal fees while leaving plaintiffs with minimal compensation. The following day, those same lawyers moved to transfer the case to a federal court, a maneuver that could delay the final approval hearing scheduled for July 9. The target court would be overseen by US District Judge Vince Chhabria in California, who earlier described the Missouri process as “legally problematic” and “dirty.”

Bayer has pushed back, with a Monsanto spokesperson characterizing objections as routine for a settlement of this scale and insisting the company will work to keep the case in state court. Lead negotiator Christopher Seeger dismissed the transfer attempt as a delay tactic. For CEO Bill Anderson, finalizing these settlements is central to restoring predictability after years of litigation over the Monsanto legacy. The next major milestone, however, may come from the US Supreme Court in late June, when the Durnell case will decide whether federal law preempts state failure-to-warn claims. A ruling in Bayer’s favor could sweep away thousands of pending suits.

Against this legal noise, Bayer’s operational performance in the first quarter of 2026 was solid by most measures. Crop Science, the unit most exposed to glyphosate, delivered adjusted revenue growth of 6.8% to €7.558 billion, while EBITDA before special items jumped 17.9% to €3.014 billion. The seeds business was the star: soybean revenue nearly doubled, including a €448 million contribution from the Corteva licensing deal, and corn seeds gained 7.1%. But the crop protection side tells a different story, with herbicide sales down 10.2% and fungicides off 10.7%. The Brazil lawsuit directly targets the weakest link.

Group-wide, adjusted revenue rose 4.1% to €13.405 billion and adjusted earnings per share climbed 12.9% to €2.71. Yet the free cash flow hole deepened to minus €2.320 billion, driven by net legal payouts of €2.002 billion, primarily for PCB and glyphosate settlements. Net financial debt swelled to €32.518 billion, underscoring the burden of past and future litigation costs. The proposed Missouri settlement would add up to $7.25 billion in capped payments spread over a maximum of 21 years, with class members able to opt out until June 4.

Bayer has reaffirmed its full-year 2026 outlook, forecasting group revenue between €44.5 billion and €46.5 billion, EBITDA before specials of €9.4 billion to €9.9 billion, and adjusted EPS of €4.10 to €4.60. The stock, trading around €38.50, remains roughly 22% below its 52-week high of €49.17 set in February. Over twelve months the shares have still gained about 57%, but an annualized volatility of nearly 34% reflects the market’s ongoing anxiety. The Brazil suit does not alter the Q1 numbers; it does, however, remind investors that the glyphosate risk is not confined to the United States — and that Bayer’s Brazilian agricultural franchise remains vulnerable.